Peter A Jones

Summary

Affiliation: University of Southern California
Country: USA

Publications

  1. pmc Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF
    Karim Bouazoune
    Department of Molecular Biology and Genetics, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Nucleic Acids Res 37:5279-94. 2009
  2. pmc Rethinking how DNA methylation patterns are maintained
    Peter A Jones
    Peter A Jones and Gangning Liang are at the Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9181, USA
    Nat Rev Genet 10:805-11. 2009
  3. pmc The epigenomics of cancer
    Peter A Jones
    Department of Urology, Biochemistry, and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cell 128:683-92. 2007
  4. pmc H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes
    Theresa K Kelly
    Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Mol Cell 39:901-11. 2010
  5. pmc DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
    Tina Branscombe Miranda
    Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Mol Cancer Ther 8:1579-88. 2009
  6. ncbi request reprint Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island
    Joy C Lin
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Cell 12:432-44. 2007
  7. ncbi request reprint Preferential response of cancer cells to zebularine
    Jonathan C Cheng
    USC Norris Comprehensive Cancer Center, Departments of Urology, Biochemistry, and Molecular Biology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Cancer Cell 6:151-8. 2004
  8. pmc DNA methylation screening identifies driver epigenetic events of cancer cell survival
    Daniel D De Carvalho
    Department of Urology, Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9181, USA
    Cancer Cell 21:655-67. 2012
  9. ncbi request reprint Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation
    Daniel J Weisenberger
    Urologic Cancer Research Laboratory, Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089 9181, USA
    Mol Cancer Res 2:62-72. 2004
  10. pmc Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA
    ShinWu Jeong
    Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, NOR 8302L, 9181, Los Angeles, CA 90089 9181, USA
    Mol Cell Biol 29:5366-76. 2009

Research Grants

  1. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter A Jones; Fiscal Year: 2010
  2. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2007
  3. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2004
  4. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2005
  5. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2005
  6. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2007
  7. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2007
  8. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2009
  9. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2003
  10. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2004

Detail Information

Publications91

  1. pmc Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF
    Karim Bouazoune
    Department of Molecular Biology and Genetics, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Nucleic Acids Res 37:5279-94. 2009
    ....
  2. pmc Rethinking how DNA methylation patterns are maintained
    Peter A Jones
    Peter A Jones and Gangning Liang are at the Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9181, USA
    Nat Rev Genet 10:805-11. 2009
    ....
  3. pmc The epigenomics of cancer
    Peter A Jones
    Department of Urology, Biochemistry, and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cell 128:683-92. 2007
    ....
  4. pmc H2A.Z maintenance during mitosis reveals nucleosome shifting on mitotically silenced genes
    Theresa K Kelly
    Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Mol Cell 39:901-11. 2010
    ..These key changes provide a potential mechanism for rapid silencing and reactivation of genes during the cell cycle...
  5. pmc DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
    Tina Branscombe Miranda
    Department of Urology, USC Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Mol Cancer Ther 8:1579-88. 2009
    ..This suggests that there is a homeostatic mechanism that returns the histone modifications to their "ground state" after DZNep treatment. Our data show the strong need for further development of histone methylation inhibitors...
  6. ncbi request reprint Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island
    Joy C Lin
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Cell 12:432-44. 2007
    ..Activation of the promoter by demethylation with 5-aza-2'-deoxycytidine involves nucleosome eviction. Epigenetic silencing of tumor suppressor genes may involve heritable changes in nucleosome occupancy enabled by cytosine methylation...
  7. ncbi request reprint Preferential response of cancer cells to zebularine
    Jonathan C Cheng
    USC Norris Comprehensive Cancer Center, Departments of Urology, Biochemistry, and Molecular Biology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Cancer Cell 6:151-8. 2004
    ..Our results demonstrate that zebularine can be selective toward cancer cells and may hold clinical promise as an anticancer therapy...
  8. pmc DNA methylation screening identifies driver epigenetic events of cancer cell survival
    Daniel D De Carvalho
    Department of Urology, Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9181, USA
    Cancer Cell 21:655-67. 2012
    ..We further showed experimentally that these genes must be silenced by DNA methylation for cancer cell survival, suggesting these are key epigenetic events associated with tumorigenesis...
  9. ncbi request reprint Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation
    Daniel J Weisenberger
    Urologic Cancer Research Laboratory, Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Los Angeles, CA 90089 9181, USA
    Mol Cancer Res 2:62-72. 2004
    ..Methylation analyses of immunodeficiency, chromosomal instabilities, and facial abnormalities cells revealed that an Alu repeat sequence was highly methylated, suggesting that Alu sequences are not DNMT3b targets...
  10. pmc Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA
    ShinWu Jeong
    Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, NOR 8302L, 9181, Los Angeles, CA 90089 9181, USA
    Mol Cell Biol 29:5366-76. 2009
    ..These data suggest that inheritance of DNA methylation requires cues from the chromatin component in addition to hemimethylation...
  11. pmc Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA molecules
    Theresa K Kelly
    Department of Urology, Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Genome Res 22:2497-506. 2012
    ....
  12. pmc Dynamic nucleosome-depleted regions at androgen receptor enhancers in the absence of ligand in prostate cancer cells
    Claudia Andreu-Vieyra
    Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089, USA
    Mol Cell Biol 31:4648-62. 2011
    ..This allows the recruitment of histone modifiers, chromatin remodelers, and ultimately gene activation. The "receptive" state described here could help explain AR signaling activation under very low ligand concentrations...
  13. pmc Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance
    Shikhar Sharma
    Department of Urology, Biochemistry, and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS Genet 7:e1001286. 2011
    ....
  14. pmc Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line
    Einav Nili Gal-Yam
    Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9181, USA
    Proc Natl Acad Sci U S A 105:12979-84. 2008
    ....
  15. ncbi request reprint Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment
    Gerda Egger
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Cancer Res 67:346-53. 2007
    ..Altogether, our data provide new insights into the mechanism of epigenetic drugs and have important implications for epigenetic therapy...
  16. pmc Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome
    Gangning Liang
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, MS 8302L, Los Angeles, CA 90089 9181
    Proc Natl Acad Sci U S A 101:7357-62. 2004
    ..Common models depicting widespread histone acetylation and K4 methylation throughout the transcribed unit do not therefore apply to the majority of human genes...
  17. doi request reprint The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2
    Jeffrey M Friedman
    Department of Urology, Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Cancer Res 69:2623-9. 2009
    ..We conclude that miR-101 may be a potent tumor suppressor by altering global chromatin structure through repression of EZH2...
  18. doi request reprint Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice
    Christine B Yoo
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90033 9181, USA
    Cancer Prev Res (Phila) 1:233-40. 2008
    ..Importantly, prolonged treatment of mice with epigenetic drugs resulted in only minor developmental and histologic changes...
  19. ncbi request reprint Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients
    Martin G Friedrich
    Departments of Urology, Clinical Pathology, and Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089 9176, USA
    Clin Cancer Res 10:7457-65. 2004
    ....
  20. pmc Gene reactivation by 5-aza-2'-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions
    Xiaojing Yang
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS Genet 8:e1002604. 2012
    ..Furthermore, we elucidate that chromatin remodeling translates the demethylation ability of DNMT inhibitors to their downstream efficacies, suggesting future therapeutic implications for chromatin remodelers...
  21. pmc DNA methylation directly silences genes with non-CpG island promoters and establishes a nucleosome occupied promoter
    Han Han
    Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90033, USA
    Hum Mol Genet 20:4299-310. 2011
    ....
  22. pmc Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival
    Gerda Egger
    Norris Comprehensive Cancer Center, Departments of Urology and Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Proc Natl Acad Sci U S A 103:14080-5. 2006
    ..Our data suggest that DNMT1 might be essential for maintenance of DNA methylation, proliferation, and survival of cancer cells...
  23. ncbi request reprint Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells
    Yoshimasa Saito
    Department of Urology, Biochemistry, and Molecular Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, USA
    Cancer Cell 9:435-43. 2006
    ..These results suggest that DNA demethylation and histone deacetylase inhibition can activate expression of miRNAs that may act as tumor suppressors...
  24. ncbi request reprint Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine
    Jody C Chuang
    USC Norris Comprehensive Cancer Center, Department of Urology, Biochemistry, and Molecular Biology, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA
    Mol Cancer Ther 4:1515-20. 2005
    ..We found that 5-Aza-CdR is far more effective in DNA methylation inhibition as well as in reactivating genes, compared with non-nucleoside inhibitors...
  25. pmc S110, a 5-Aza-2'-deoxycytidine-containing dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce tumor growth
    Jody C Chuang
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Mol Cancer Ther 9:1443-50. 2010
    ..We also show that S110 is effective by both i.p. and s.c. deliveries. S110 therefore is a promising new agent that acts similarly to 5-Aza-CdR and has better stability and less toxicity...
  26. pmc Unique DNA methylation patterns distinguish noninvasive and invasive urothelial cancers and establish an epigenetic field defect in premalignant tissue
    Erika M Wolff
    Department of Urology, USC Epigenome Center, and Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, University of Southern California, Keck School of Medicine, Los Angeles, CA 90089, USA
    Cancer Res 70:8169-78. 2010
    ..In addition, an epithelium-wide epigenetic defect in bladders with cancer might contribute to a loss of epithelial integrity and create a permissible environment for tumors to arise...
  27. ncbi request reprint Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine
    Carvell T Nguyen
    Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center and Hospital, University of Southern California, Keck School of Medicine, Los Angeles, California 90089, USA
    Cancer Res 62:6456-61. 2002
    ..In addition, 5-Aza-CdR increased acetylation and H3-K4 methylation at the unmethylated p14 promoter, suggesting it can induce chromatin remodeling independently of its effects on cytosine methylation...
  28. pmc Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer
    Erika M Wolff
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS Genet 6:e1000917. 2010
    ..These data show that, in addition to contributing to chromosomal instability, hypomethylation of LINE-1s can alter the functional transcriptome and plays a role not only in human disease but also in disease predisposition...
  29. pmc Polycomb-repressed genes have permissive enhancers that initiate reprogramming
    Phillippa C Taberlay
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Cell 147:1283-94. 2011
    ..Genome-wide, a high percentage of Polycomb targets are associated with putative enhancers in permissive states, suggesting that they may provide a widespread avenue for the initiation of cell-fate reprogramming...
  30. ncbi request reprint Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides
    Christine B Yoo
    Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
    Cancer Res 67:6400-8. 2007
    ..This approach may pave the way for more stable and potent inhibitors of DNA methylation as well as provide means for improving existing therapeutics...
  31. ncbi request reprint Prognostic relevance of methylation markers in patients with non-muscle invasive bladder carcinoma
    Martin G Friedrich
    Department of Urology, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90089 9176, USA
    Eur J Cancer 41:2769-78. 2005
    ..We identified one gene (TIMP-3) where methylation was associated with a more favourable outcome. Our data strongly support the usefulness of gene methylation as a prognostic marker in patients with non-muscle invasive bladder cancer...
  32. pmc OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes
    Jueng Soo You
    Department of Urology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Proc Natl Acad Sci U S A 108:14497-502. 2011
    ..These data show the central role of the NDRs, established by OCT4, in ensuring the autoregulatory loop of pluripotency and, furthermore, that de novo methylation follows the loss of NDRs and stabilizes the suppressed state...
  33. pmc Constitutive nucleosome depletion and ordered factor assembly at the GRP78 promoter revealed by single molecule footprinting
    Einav Nili Gal-Yam
    Department of Urology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
    PLoS Genet 2:e160. 2006
    ..Studying the positioning of nucleosomes and transcription factors at the single promoter level provides a powerful tool to gain novel insights into the transcriptional process in eukaryotes...
  34. ncbi request reprint Cell division is required for de novo methylation of CpG islands in bladder cancer cells
    Mihaela Velicescu
    Urologic Cancer Research Laboratory, Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90089 9181, USA
    Cancer Res 62:2378-84. 2002
    ..Our results suggest that cell division is required for de novo methylation of CpG islands and that DNMT3a may play a role in methylating CpG poor regions or repetitive DNA elements outside of the S phase of the cell cycle...
  35. ncbi request reprint Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction
    Gangning Liang
    Department of Biochemistry and Molecular Biology, Urologic Cancer Research Laboratory, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Methods 27:150-5. 2002
    ..We have demonstrated that this technique is a rapid and efficient method that can be used to screen for altered methylation patterns in genomic DNA and to isolate specific sequences associated with these changes...
  36. pmc Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells
    Jonathan C Cheng
    Department of Urology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9181, USA
    Mol Cell Biol 24:1270-8. 2004
    ..Last, sequential treatment with 5-aza-2'-deoxycytidine followed by zebularine hindered the remethylation of the p16 5' region and gene resilencing, suggesting the possible combination use of both drugs as a potential anticancer regimen...
  37. pmc Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine
    Christine B Yoo
    Department of Biochemistry, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Med Chem 51:7593-601. 2008
    ..Intriguingly, the activity of the ProTides was cell line-dependent, and activation of p16 was manifest only in Cf-Pac-1 pancreatic ductal adenocarcinoma cells...
  38. pmc Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells
    Li Jia
    Department of Urology, Norris Cancer Center, USC Keck School of Medicine, Los Angeles, California, USA
    Mol Cell Biol 26:7331-41. 2006
    ..These features contribute to the androgen-independent phenotype of these cells...
  39. pmc Establishment of active chromatin structure at enhancer elements by mixed-lineage leukemia 1 to initiate estrogen-dependent gene expression
    Kwang Won Jeong
    Gachon Institute of Pharmaceutical Sciences, College of Pharmacy, Gachon University, Incheon 406 840, Republic of Korea, Departments of Urology and Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9176, USA, Department of Biochemistry, School of Medicine, Konkuk University, Seoul 143 701, Republic of Korea and Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9176, USA
    Nucleic Acids Res 42:2245-56. 2014
    ....
  40. pmc Functional DNA demethylation is accompanied by chromatin accessibility
    Kurinji Pandiyan
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033 USA
    Nucleic Acids Res 41:3973-85. 2013
    ....
  41. ncbi request reprint DNA methylation: the nuts and bolts of repression
    Tina Branscombe Miranda
    Department of Urology, Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    J Cell Physiol 213:384-90. 2007
    ..In this review, we will discuss the mechanisms which lead to the long-term silencing of genes and will survey the progression that has been made in determining the targeted mechanisms for de novo DNA methylation...
  42. ncbi request reprint Identification and characterization of alternatively spliced variants of DNA methyltransferase 3a in mammalian cells
    Daniel J Weisenberger
    Urologic Cancer Research Laboratory, Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, 1441 Eastlake Avenue, Room 8302L, Los Angeles, CA 90089 9181, USA
    Gene 298:91-9. 2002
    ..The preferential expression of the beta transcript in ES cells suggests that this transcript, in addition to Dnmt3a2, may also be important for de novo methylation during development...
  43. pmc Targeting DNA methylation for epigenetic therapy
    Xiaojing Yang
    Department of Urology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Trends Pharmacol Sci 31:536-46. 2010
    ..This review delineates the latest cancer epigenetic models, the recent discovery of hypomethylation agents as well as their application in the clinic...
  44. ncbi request reprint Discovery of epigenetically masked tumor suppressor genes in endometrial cancer
    Noriyuki Takai
    Division of Hematology Oncology, Cedars Sinai Medical Center University of California at Los Angeles School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Mol Cancer Res 3:261-9. 2005
    ..Our data suggest that C/ebpalpha and Tig1 function as tumor suppressor proteins in endometrial cancers and that their reexpression may be a therapeutic target...
  45. pmc Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level
    Mehrnaz Fatemi
    Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California Los Angeles, CA 90089 9181, USA
    Nucleic Acids Res 33:e176. 2005
    ..Our high resolution approach gives a 'digitized' visualization of each promoter providing information regarding nucleosome occupancy and may be utilized to define transcription factor binding and chromatin remodeling...
  46. pmc Reprogramming of the human intestinal epigenome by surgical tissue transposition
    Fides D Lay
    Department of Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Genome Res 24:545-53. 2014
    ....
  47. ncbi request reprint Cancer epigenetics: modifications, screening, and therapy
    Einav Nili Gal-Yam
    Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles 90089, USA
    Annu Rev Med 59:267-80. 2008
    ..We review these modifications in normal and cancer cells and the evolving approaches used to study them. Additionally, we outline advances in their potential use for cancer diagnostics and targeted epigenetic therapy...
  48. pmc RUNX3 methylation reveals that bladder tumors are older in patients with a history of smoking
    Erika M Wolff
    Department of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089, USA
    Cancer Res 68:6208-14. 2008
    ..Because RUNX3 methylation is acquired early on in tumorigenesis, then its detection in biopsy or urine specimens could provide a marker to screen cigarette smokers long before any symptoms of bladder cancer are present...
  49. pmc DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight
    Daniel J Weisenberger
    Department of Surgery, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA
    Nucleic Acids Res 36:4689-98. 2008
    ..Using digital MethyLight, we identified single-molecule, cancer-specific DNA hypermethylation events in the CpG islands of RUNX3, CLDN5 and FOXE1 present in plasma samples from breast cancer patients...
  50. ncbi request reprint Epigenetics and microRNAs
    Jody C Chuang
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles 90089, USA
    Pediatr Res 61:24R-29R. 2007
    ..We examine the effects of miRNAs on epigenetic machinery, and the control of miRNA expression by epigenetic mechanisms. Epigenetics is defined as heritable changes in gene expression that do not involve a change in DNA sequence...
  51. pmc Chromatin, cancer and drug therapies
    Connie C Cortez
    Department of Urology, University of Southern California, Los Angeles, CA 90089 9181, USA
    Mutat Res 647:44-51. 2008
    ..Progress has been made in the treatment of hematological malignancies and some solid tumors. As the knowledge of how chromatin regulates gene expression is enhanced, improvements in the treatment of cancer can be made...
  52. ncbi request reprint Epigenetics in carcinogenesis and cancer prevention
    Peter A Jones
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089 9181, USA
    Ann N Y Acad Sci 983:213-9. 2003
    ....
  53. ncbi request reprint Methylation-sensitive single-molecule analysis of chromatin structure
    Tina B Miranda
    Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
    Curr Protoc Mol Biol . 2010
    ..SssI), followed by bisulfite sequencing of individual progeny DNA molecules. Unlike nuclease-based approaches, this method allows each molecule to be viewed as an individual entity instead of an average population...
  54. pmc SNF5 is an essential executor of epigenetic regulation during differentiation
    Jueng Soo You
    Departments of Urology and Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angles, California, United States of America
    PLoS Genet 9:e1003459. 2013
    ..Together, we demonstrate that SNF5 executes the switch between pluripotency and differentiation...
  55. ncbi request reprint Epigenetics in human disease and prospects for epigenetic therapy
    Gerda Egger
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, Room 8302L, Los Angeles, California 90089 9181, USA
    Nature 429:457-63. 2004
    ....
  56. ncbi request reprint DNA methylation and cancer
    Peter A Jones
    USC Norris Comprehensive Cancer Center, Department of Urology, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, MS 8302L, Los Angeles, California, CA 90089 9181
    Oncogene 21:5358-60. 2002
    ..Understanding these processes is fundamental to understanding what goes awry during the process of aging and carcinogenesis where DNA methylation patterns become substantially altered and contribute to the malignant phenotype...
  57. ncbi request reprint p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer
    Ben George
    Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA 90033, USA
    J Clin Oncol 25:5352-8. 2007
    ..This study evaluated the clinical relationship of the p53 gene and protein statuses...
  58. ncbi request reprint Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine
    Gangning Liang
    USC Norris Comprehensive Cancer Center, Department of Urology, Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9181, USA
    Cancer Res 62:961-6. 2002
    ..Interestingly, a high percentage of genes activated in both cell types belonged to the IFN signaling pathway, confirming data from other tumor cell types...
  59. ncbi request reprint A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence
    Sheng Fang Su
    Authors Affiliations Departments of Urology and Preventive Medicine Program in Genetic, Molecular, and Cellular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles and Department of Urology, School of Medicine, University of Stanford, Stanford, California
    Clin Cancer Res 20:1978-89. 2014
    ..Some urine markers have been used to help detect bladder tumors; however, their use in longitudinal tumor recurrence surveillance has yet to be established...
  60. ncbi request reprint Epigenetic activation of tumor suppressor microRNAs in human cancer cells
    Yoshimasa Saito
    Department of Urology, Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA
    Cell Cycle 5:2220-2. 2006
    ..Activation of tumor suppressor miRNAs by chromatin modifying drugs may cause downregulation of target oncogenes and could be a novel strategy for the prevention and treatment of human cancer...
  61. ncbi request reprint DNA methylation and cancer
    Phillippa C Taberlay
    Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Prog Drug Res 67:1-23. 2011
    ..Here, we will discuss the importance of both established and novel molecular concepts that may underlie the role of DNA methylation in cancer...
  62. pmc Epigenetics in cancer
    Shikhar Sharma
    Department of Urology, Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9181, USA
    Carcinogenesis 31:27-36. 2010
    ....
  63. pmc Differentially methylated alleles in a distinct region of the human interleukin-1alpha promoter are associated with allele-specific expression of IL-1alpha in CD4+ T cells
    Johanna G I van Rietschoten
    Department of Urology, Biochemistry, and Molecular Biology, Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Ave, Rm 7341, Los Angeles, CA 90089 9181, USA
    Blood 108:2143-9. 2006
    ..Taken together, these results suggest that allele-specific expression of IL-1alpha in CD4+ cells is achieved, at least in part, by differential methylation of the promoter...
  64. ncbi request reprint Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome
    Daiya Takai
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA
    Mol Biol Evol 21:463-7. 2004
    ..This exclusion might be responsible for the existence of these divergent transcripts...
  65. ncbi request reprint Epigenetic therapy of cancer: past, present and future
    Christine B Yoo
    USC Norris Comprehensive Cancer Center, Department of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Los Angeles, California 90089, USA
    Nat Rev Drug Discov 5:37-50. 2006
    ....
  66. pmc Cancer genetics and epigenetics: two sides of the same coin?
    Jueng Soo You
    Department of Urology, USC Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA
    Cancer Cell 22:9-20. 2012
    ..This crosstalk between the genome and the epigenome offers new possibilities for therapy...
  67. pmc Lysine methyltransferase G9a is not required for DNMT3A/3B anchoring to methylated nucleosomes and maintenance of DNA methylation in somatic cells
    Shikhar Sharma
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089 9181, USA
    Epigenetics Chromatin 5:3. 2012
    ..abstract:..
  68. ncbi request reprint An epigenetic approach for finding tumor suppressors
    Peter A Jones
    Department of Urology, USC Norris Comprehensive Cancer Center, Los Angeles, CA 90089 9181, USA
    Cell Cycle 2:25-6. 2003
  69. ncbi request reprint DNA methylation and breast carcinogenesis
    Martin Widschwendter
    USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, MS 8302L, Los Angeles, California, CA 90089 9181, USA
    Oncogene 21:5462-82. 2002
    ....
  70. ncbi request reprint Quantitative methylation analysis using methylation-sensitive single-nucleotide primer extension (Ms-SNuPE)
    Mark L Gonzalgo
    Department of Biochemistry and Molecular Biology, Urologic Cancer Research Laboratory, USC Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90089 9181, USA
    Methods 27:128-33. 2002
    ..The Ms-SNuPE technique can be adapted for high-throughput methylation analysis and therefore represents a novel approach for rapid quantitation of cytosine methylation suitable for a wide range of biological investigations...
  71. pmc DNA methylation and cellular reprogramming
    Daniel D De Carvalho
    Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
    Trends Cell Biol 20:609-17. 2010
    ..Elucidation of the epigenetic changes taking place during cellular reprogramming will enhance our understanding of stem cell biology and facilitate therapeutic applications...
  72. pmc MicroRNAs: critical mediators of differentiation, development and disease
    Jeffrey M Friedman
    Department of Urology, Biochemistry and Molecular Biology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Swiss Med Wkly 139:466-72. 2009
    ..Moreover, many disease states, including cancer, occur or are sustained by miRNA dysregulation. In this article, the latest reports of miRNA involvement and aberrant expression in human disease are reviewed, with an emphasis on cancer...
  73. ncbi request reprint A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop
    Peter A Jones
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, 90089, USA
    Cancer Res 65:11241-6. 2005
    ..A timely workshop of leading experts, convened by the American Association for Cancer Research (AACR), confirmed that the technology is at hand to begin defining human epigenomes at high resolution...
  74. doi request reprint Molecular targets and targeted therapies in bladder cancer management
    Ramy F Youssef
    Departments of Pathology, Keck School of Medicine and Norris Comprehensive Cancer Center, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA, 90033, USA
    World J Urol 27:9-20. 2009
    ..The current status of targeted therapies for bladder cancer is also presented as well as the ongoing clinical trials...
  75. ncbi request reprint Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen
    Martin Widschwendter
    Department of Urology, University of Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center, Los Angeles, California, 90089 9176, USA
    Cancer Res 64:3807-13. 2004
    ....
  76. pmc Comprehensive analysis of CpG islands in human chromosomes 21 and 22
    Daiya Takai
    Department of Biochemistry and Molecular Biology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA
    Proc Natl Acad Sci U S A 99:3740-5. 2002
    ..This finding is compatible with the recent detection of 5-methylcytosine in Drosophila, and might suggest that S. cerevisiae has, or once had, CpG methylation...
  77. ncbi request reprint The fundamental role of epigenetic events in cancer
    Peter A Jones
    USC Norris Comprehensive Cancer Center, Department of Urology, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, MS 8302L, Los Angeles, California 90089 9181, USA
    Nat Rev Genet 3:415-28. 2002
    ..In this review, we discuss these epigenetic events and the molecular alterations that might cause them and/or underlie altered gene expression in cancer...
  78. ncbi request reprint Overview of cancer epigenetics
    Peter A Jones
    Department of Urology, University of Southern California Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90089 9181, USA
    Semin Hematol 42:S3-8. 2005
    ..In addition, changed patterns of methylation can be detected with a high degree of sensitivity thus providing clinicians with prognostic information...
  79. ncbi request reprint Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer
    Erika M Wolff
    Department of Biochemistry, University of Southern California, Los Angeles, CA 90089, USA
    Nat Clin Pract Urol 2:502-10. 2005
    ..This review examines the published data and proposes a model for the mechanisms behind bladder cancer development...
  80. ncbi request reprint The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., D
    Martin Widschwendter
    University of Southern California Norris Comprehensive Cancer Center, Department of Biochemistry and Molecular Biology, Keck School of Medicine, University of Southern California, Los Angeles, California 90089 9181, USA
    Clin Cancer Res 8:17-21. 2002
  81. pmc Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements
    Gangning Liang
    USC Norris Comprehensive Cancer Center, Department of Urology, Keck School of Medicine of the University of Southern California, Los Angeles, California 90089 9181, USA
    Mol Cell Biol 22:480-91. 2002
    ..Our results reveal a previously unrecognized degree of cooperativity among mammalian DNA methyltransferases in ES cells...
  82. ncbi request reprint The CpG island searcher: a new WWW resource
    Daiya Takai
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, USA
    In Silico Biol 3:235-40. 2003
    ..The CpG Island Searcher is available on the World Wide Web at http://www.cpgislands.com or http://www.uscnorris.com/cpgislands/cpg.cgi...
  83. pmc Establishment of conditional vectors for hairpin siRNA knockdowns
    Shiro Matsukura
    Department of Biochemistry and Molecular Biology, USC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    Nucleic Acids Res 31:e77. 2003
    ..Removal of the inducer, doxycycline, from treated cells led to re-expression of the targeted gene. Thus the method allows for a highly controlled approach to gene knockdown...
  84. ncbi request reprint Epigenetic changes in cancer
    Kirsten Grønbaek
    Department of Hematology, Rigshospitalet, Copenhagen, Denmark
    APMIS 115:1039-59. 2007
    ....
  85. ncbi request reprint Meddling with methylation
    Chih Lin Hsieh
    Nat Cell Biol 5:502-4. 2003
  86. ncbi request reprint Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment
    Michael Daskalakis
    Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany
    Blood 100:2957-64. 2002
    ....
  87. ncbi request reprint Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy
    Victor E Marquez
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, NIH, Frederick, Maryland 21702, USA
    Ann N Y Acad Sci 1058:246-54. 2005
    ..The latter activity makes zebularine a promising antitumor agent that is hydrolytically stable, preferentially targets cancer cells, and shows activity both in vitro and in experimental animals, even after oral administration...
  88. ncbi request reprint Inhibition of DNA methylation and reactivation of silenced genes by zebularine
    Jonathan C Cheng
    University of Southern California Norris Comprehensive Cancer Center and Hospital, Department of Biochemistry and Molecular Biology, USC Keck School of Medicine, Los Angeles 90089, USA
    J Natl Cancer Inst 95:399-409. 2003
    ..We characterized a new demethylating agent, zebularine [1-(beta-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one], which is a chemically stable cytidine analog...
  89. ncbi request reprint Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer
    Sunanda J Chatterjee
    Department of Pathology, USC Norris Cancer Center, 1441 Eastlake Avenue, Los Angeles, CA 90033, USA
    J Pathol 203:762-70. 2004
    ..Immunohistochemical expression of pRb appears to be a reliable indicator of pRb function...
  90. ncbi request reprint Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology
    Victor E Marquez
    Laboratory of Medicinal Chemistry, Center for Cancer Research, NCI at Frederick, NIH, Frederick, MD 21702, USA
    Nucleosides Nucleotides Nucleic Acids 24:305-18. 2005
    ..Zebularine is a stable, antitumor agent that preferentially targets cancer cells and shows activity both in vitro and in experimental animals, even after oral administration...

Research Grants28

  1. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter A Jones; Fiscal Year: 2010
    ....
  2. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2007
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  3. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2004
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  4. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2005
    ..Once in DNA, it functions as a mechanism-based inhibitor of DNA methyltransferase and appears to show specificity for the DNMT1 enzyme. This drug is orally active and might possibly find use as a chemotherapeutic agent. ..
  5. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2005
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  6. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2007
    ..Once in DNA, it functions as a mechanism-based inhibitor of DNA methyltransferase and appears to show specificity for the DNMT1 enzyme. This drug is orally active and might possibly find use as a chemotherapeutic agent. ..
  7. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2007
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  8. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2009
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  9. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2003
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  10. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2004
    ..Once in DNA, it functions as a mechanism-based inhibitor of DNA methyltransferase and appears to show specificity for the DNMT1 enzyme. This drug is orally active and might possibly find use as a chemotherapeutic agent. ..
  11. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2001
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  12. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2000
    ..abstract_text> ..
  13. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2001
    ..abstract_text> ..
  14. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2002
    ..abstract_text> ..
  15. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2002
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  16. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2006
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  17. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2003
    ..abstract_text> ..
  18. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2005
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  19. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 2006
    ..Once in DNA, it functions as a mechanism-based inhibitor of DNA methyltransferase and appears to show specificity for the DNMT1 enzyme. This drug is orally active and might possibly find use as a chemotherapeutic agent. ..
  20. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2006
    ..Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease. ..
  21. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2003
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  22. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2004
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  23. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2004
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  24. DE NOVO DNA METHYLATION IN BLADDER CANCER
    Peter Jones; Fiscal Year: 2003
    ..The investigators believe that the application of the non-directed MS-AP-PCR approach to a well understood tumor such as bladder cancer at different stages of progression will provide answers to some of the key questions in this field. ..
  25. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter Jones; Fiscal Year: 1999
    ..abstract_text> ..